Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
There were several individual predictors including sex, age, recent visits with a primary care provider, distance to nearest endoscopy facility, and insurance type, as well as county-level predictors, such as percentage of residents with a high school education, without insurance, and unemployed as being up-to-date.
The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.
The threshold values for the SOF/VEL prophylaxis strategies showed that the 4-week strategy likely won’t be less costly under any reasonable value of the input variables.
There were higher percentages of patients treated with mirikizumab that had clinical remission at week 12 of the induction trial compared to the placebo group. This was also true at week 40 of the maintenance trial.
Headache, pruritis, fatigue, eosinophilia, injection-site reactions, upper abdominal pain, arthralgia, and asthenia were more common in the bulevirtide group compared to the control group.
In recent years trial designs have evolved to become increasingly complex and sophisticated with new endpoints that could include patient-reported outcomes, biomarkers, mucosal, and histological healing, central endoscopy reading, and trials that examine both induction and maintenance of remission within the same study.
The American Academy of Sleep Medicine revised the guidelines for REM sleep behavior disorder for the first time since 2010.
BOS-580 is an investigational, proprietary, long-acting fibroblast growth factor 21 analog as a monthly and bi-weekly treatment for patients with NASH.
Telehealth likely will have a major place in psychiatric care in the future.
For participants reporting past-year suicidal experiences, there was decreased odds of attributing their suicidal experiences to the pandemic for veterans compared to nonveterans.
The investigators found an adjusted odds ratio of 1.74 for hospitalized suicide attempts and 1.45 for those who committed suicide in individuals with recent psychiatric history.
The guidelines contain safety warnings because psychedelic drugs could produce psychoactive effects such as mood, cognitive changes, and hallucinations.
The treatment, developed by Intercept Pharmaceuticals, could not be approved in its present form, according to the CRL and any resubmission of the treatment for patients with NASH would require at least the successful completion of the long-term outcomes phase of the REGENERATE study.
The results show 55.4% of patients in the ketamine group had a response, compared to 41.2% of patients in the ECT group.
Patients with high attendance rates within the lifestyle intervention group lost more weight than those with medium and low rates.
Patients with anxiety or depression who engaged in health-related social media usage were significantly more likely to report to report intentions to quit smoking, endorse past 12-month attempts at smoking cessation, and were more likely to meet national recommendation for weekly strength training.
The results show high centrality of anxiety and depression in patients with COVID-19 and anxiety had the highest bridge influence in the network.
After making adjustments, the results show a positive association between alcohol dependence at 18 years and depression at age 24 years. However, there was no association between the rate of change and depression.
The new guidelines call for MDD screening for adults, including pregnant and postpartum individuals and those aged 65 years and older, which would have a moderate net benefit.
NLR values were similar between significant and minimal fibrosis and were not correlated with significant fibrosis.
Patients with anti-HDV antibodies had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV co-infection compared to patients who demonstrated serum anti-HDV antibody negatively.
Men who have sex with men in Europe were more likely to be in a cluster compared to non-European men who have sex with men.
The US Food and Drug Administration (FDA) approved linaclotide earlier this month for the treatment of patients with functional constipation aged 6-17 years.
The race-neutral model resulted in worse calibration, NPV, and false-negative rates among racial and ethnic minority subgroups compared to non-Hispanic White participants.
In the phase 2b ORIGIN trial, atacicept resulted in a statistically significant reduction in mean proteinuria compared to baseline at week 24.
There were no new safety signals identified from the COMMAND trial.
In the maintenance period, 86% of patients treated icanbelimod completed and 67% achieved clinical remission through week 48.
The point prevalence per 100,000 people at the conclusion of the study was 71.8 for autoimmune hepatitis, 38.5 for primary biliary cholangitis, and 11.0 for primary sclerosing cholangitis.
For individuals with hepatitis C virus infections, 52.5% of deaths were deemed attributable to the infection.
Patients with autoimmune hepatitis who were positive for antimitochondrial antibodies and evidence of non-specific bile duct injury had a higher risk of progressing to cirrhosis.
January 16th 2021
March 3rd 2021
